Linagliptin CAS 668270-12-0 Puritas ≥99.0% (HPLC) Factory
Manufacturer Supple, Puritas, Commercial Productio
Nomen chemicum: Linagliptin
CAS: 668270-12-0
Nomen chemicum | Linagliptin |
Synonyma | BI-1356;8-[(3R) -3-Amino-1-piperidinyl]-7-(2-butynyl) -3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1H -purine-2,6-dione |
CAS Number | 668270-12-0 |
CATTUS Number | RF-API105 |
Stock Status | In Stock, Productio Ascendite ad Tons |
Formulae hypotheticae | C25H28N8O2 |
M. Pondus | 472.54 |
Liquescens punctum | 197.0 ad 200.0℃ |
Solubilitas | Solutum in DMSO |
Brand | Ruifu Chemical |
Item | Specifications |
Aspectus | Alba vel Off-White Crystalline pulveris |
NMR | Congruunt cum Structure |
Puritas / Analysis Methodus | ≥99.0% (HPLC) |
Damnum in Siccatio | ≤0.50% |
Residere in Ignition | ≤0.10% |
Metalla gravis | ≤10ppm |
Substantiae cognatae | |
una immunditia | ≤0.50% |
Totalis immunditias | ≤1.0% |
Isomer | ≤0.15% |
RELICTUM Solvents | |
Methanol | ≤3000ppm |
Isopropanol | ≤5000ppm |
DMF | ≤800ppm |
Dichloromethane | ≤600ppm |
Test Standard | Enterprise Standard |
Consuetudinem | API |
sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris.
Repono Condition:Repone in vasis signatis in loco frigido et sicco;A luce et humore protege.
Linagliptin (CAS: 668270-12-0) est DPP-IV inhibitor a Boehringer Ingelheim elaboratus ad tractationem speciei II diabete.Duae notae pharmacologicae quae linagliptin ab aliis DPP-4 inhibitoribus ponit, est quod profile pharmacokineticae non lineari habet nec praesertim a systemate renali removetur.Linagliptin (olim-die) ab US FDA probatus est die 2 mensis Maii anno 2011 ad tractationem speciei II diabete.Apud Boehringer Ingelheim et Lilium venales est.Linagliptin, ven- titio sub nomine Tradjenta in aliis.Utitur una cum exercitatione et victu.